As of the beginning of next year, 2024, you may no longer be able to receive support for the weight loss drug (Wegovy injection) from Danish health insurance, according to a statement by Allan Loblaw, director of Sygeforsikringen Denmark, to the DR website, in which he stated that the demand for the slimming drug has increased significantly, which means for insurance an increase in spending on this type of drug. If the demand continues to increase in this way, then support may be reduced or canceled entirely.
The insurance currently covers up to 50% of the cost
ويتكلف استخدام Wegovy ما بين 17000 و 31000 كرون سنوياً اعتماداً على الفئة التي تنتمي إليها في التأمين الصحي الدنماركي، حيث يغطي التأمين 25 – 50% من تكلفتها.
A prescription is required to purchase the medication.
The drug cannot be purchased without a doctor's prescription. It is intended to help people with severe obesity lose weight. This drug has been approved to treat people with a body mass index (BMI) over 30 or a BMI of 27 with co-morbidities such as diabetes. According to the Danish Health Authority's Pharmacotherapy Efforts (IRF), weight loss is generally expected to be maintained only with continued treatment using Wegovy.
Side effects of the drug
The research shows that the treatment can greatly make it easier for obese people to lose weight, however it is not without side effects and risks.
Side effects manifest as symptoms such as abdominal pain, nausea, diarrhea, constipation, and vomiting.
The Danish Medicines Agency refused to provide public funding for the drug. The drug's manufacturer is the well-known Danish company Novo Nordisk. It consists of injections containing the active ingredient semaglutide, which the patient injects under the skin once a week. The drug works by reducing the feeling of hunger, and it is also available in the United States.
-
-
-
-
